Precision Diabetes and DirectSens to introduce MetMark test in US

Precision Diabetes has signed a US commercialisation partnership with DirectSens for the MetMark clinical test, which measures AHB; 2-HB, a biomarker associated with metabolic dysfunction and future type 2 diabetes risk. DirectSens will supply the assay technology, product documentation and technical onboarding. The partnership follows two studies in 2026 examining AHB in relation to glucose regulation and type 2 diabetes risk. Credit: Andrzej Rostek/Shutterstock.com. Precision Diabetes has signed a US commercialisation partnership with DirectSens for the MetMark clinical test, which measures alpha-hydroxybutyrate (AHB; 2-HB), a biomarker associated with metabolic dysfunction and future type 2 diabetes (T2D) risk. MetMark will be…

Source: Medical Device Network